Please check your internet connection and try again.
# Tabgenixim (Cefixime)
## Overview
Tabgenixim is a brand name for **Cefixime**, a third-generation cephalosporin antibiotic. It possesses broad-spectrum activity against many Gram-negative bacteria and selected Gram-positive organisms. It is stable against many beta-lactamases.
## Primary Indications
* Uncomplicated urinary tract infections (UTIs)
* Otitis media
* Pharyngitis and tonsillitis
* Acute bronchitis and acute exacerbations of chronic bronchitis
* Uncomplicated gonorrhea (cervical/urethral/rectal)
## Adult Dosing
* **General infections:** 400 mg daily, administered either as a single dose or in two divided doses (200 mg every 12 hours).
* **Uncomplicated gonorrhea:** 800 mg as a single oral dose.
## Pediatric Dosing
* **General infections:** 8 mg/kg/day, administered as a single daily dose or in two divided doses (4 mg/kg every 12 hours).
* **Max daily dose:** 400 mg.
* *Note: Dosing for children weighing >50 kg or >12 years of age should follow adult guidelines.*
## Dose Adjustments
* **Renal Impairment:**
* CrCl 21–60 mL/min: Reduce dose to 75% of the standard dose (give 300 mg daily).
* CrCl <20 mL/min: Reduce dose to 50% of the standard dose (give 200 mg daily).
* **Hepatic Impairment:** No specific adjustment required.
## Contraindications
* Known hypersensitivity to cefixime or other cephalosporins.
* History of severe allergic reactions (e.g., anaphylaxis) to penicillins or other beta-lactams (caution advised due to potential cross-reactivity).
## Adverse Effects
* **Common:** Diarrhea (often dose-dependent), abdominal pain, nausea, dyspepsia.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity reactions (rash, pruritus), rare cases of Stevens-Johnson syndrome or toxic epidermal necrolysis.
## Key Drug Interactions
* **Anticoagulants:** May increase the anticoagulant effect of Warfarin (monitor INR).
* **Probenecid:** Increases serum concentrations of cefixime by decreasing renal tubular secretion.
* **Salicylates:** May increase plasma levels of cefixime.
## Monitoring
* Monitor for resolution of infection symptoms.
* Assess for signs of *C. difficile* infection (persistent diarrhea, abdominal cramping).
* Monitor renal function in patients with pre-existing impairment or long-term therapy.
## Clinical Pearls
* Cefixime suspension should be shaken well before use.
* Oral absorption is not significantly affected by food.
* Not effective against *Staphylococcus aureus* or *Pseudomonas aeruginosa*.
* For empiric gonorrhea treatment, current CDC guidelines emphasize dual therapy or specific high-dose regimens; confirm local resistance patterns.
***
**Disclaimer:** This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors before administration. Consult the latest FDA-approved labeling or medication databases.
